NASDAQ · CBUS
Healthcare · Biotechnology
$1.14
Up+$0.10 (+8.77%)
Updated Nov 4, 2026, 11:21 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CBUS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CBUS closed at $1.14 after 21 trading sessions, down 27.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $1.24 | $1.29 | $1.12 | $1.14 | 123.98K |
| Nov 2, 2026 | $1.365 | $1.38 | $1.22 | $1.24 | 76.67K |
| Oct 30, 2026 | $1.36 | $1.395 | $1.27 | $1.29 | 52.98K |
| Oct 29, 2026 | $1.45 | $1.45 | $1.31 | $1.35 | 52.16K |
| Oct 28, 2026 | $1.37 | $1.45 | $1.35 | $1.41 | 60.66K |
| Oct 27, 2026 | $1.40 | $1.47 | $1.3506 | $1.38 | 56.01K |
| Oct 26, 2026 | $1.42 | $1.42 | $1.34 | $1.395 | 51.29K |
| Oct 23, 2026 | $1.37 | $1.44 | $1.34 | $1.41 | 45.98K |
| Oct 22, 2026 | $1.38 | $1.47 | $1.35 | $1.40 | 47.32K |
| Oct 21, 2026 | $1.40 | $1.43 | $1.38 | $1.41 | 48.8K |
| Oct 20, 2026 | $1.33 | $1.45 | $1.32 | $1.39 | 56.95K |
| Oct 19, 2026 | $1.34 | $1.38 | $1.28 | $1.31 | 36.77K |
| Oct 16, 2026 | $1.30 | $1.35 | $1.285 | $1.32 | 45.71K |
| Oct 15, 2026 | $1.40 | $1.46 | $1.26 | $1.29 | 79.38K |
| Oct 14, 2026 | $1.42 | $1.44 | $1.35 | $1.40 | 106.58K |
| Oct 13, 2026 | $1.49 | $1.50 | $1.36 | $1.41 | 45.28K |
| Oct 12, 2026 | $1.51 | $1.57 | $1.435 | $1.48 | 90.75K |
| Oct 9, 2026 | $1.60 | $1.6399 | $1.52 | $1.55 | 44.22K |
| Oct 8, 2026 | $1.62 | $1.64 | $1.57 | $1.59 | 149.07K |
| Oct 7, 2026 | $1.56 | $1.64 | $1.50 | $1.62 | 99.21K |
| Oct 6, 2026 | $1.67 | $1.73 | $1.56 | $1.57 | 164.43K |
The latest Smart Investors Daily articles mentioning CBUS.
Company
Market Activity
Research & News
CBUS research
Company profile and research snapshot.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | Jefferies | Hold | — |
| Dec 8, 2025 | Canaccord Genuity | Buy | — |
| May 12, 2025 | Canaccord Genuity | Buy | — |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 22, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 6, 2026
Cibus to utilize proprietary Rapid Trait Development System™ to enable development of durable resistance to Light Leaf Spot disease, which has caused estimated yield losses of up to £300m in recent yearsSAN DIEGO,
Benzinga · Jan 29, 2026
Benzinga · Jan 29, 2026
The Company has also granted the underwriter a 30-day option to purchase up to an additional 1,999,999 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the
Benzinga · Jan 28, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CBUS.
